Raime Leeby Muhle, who has worked in a variety of industries including technology, distribution, manufacturing, and telecommunications for 18 years, is the CFO of Centennial, Colorado-based AlloSource.
Raime Leeby Muhle New CFO of AlloSource
1 min read Premium comments
Secondary
According to the company, “With over 18 years of experience, Leeby Muhle’s background spans from emerging high growth businesses to large and mature organizations. She has worked in a variety of industries including technology, distribution, manufacturing, and telecommunications. Leeby Muhle’s expertise in complex environments, as well as working cross-functionally, will help her lead the accounting, financial, and information technology teams at AlloSource. Leeby Muhle is taking over for current Chief Financial Officer, Olivia Thompson, who is transitioning into retirement to focus on project-based work.”
“We are thrilled to welcome Raime to our executive team,” said Thomas Cycyota, AlloSource president and CEO. “Her financial expertise and leadership, as well as her passion for our mission, will help drive AlloSource’s growth as we continue to evolve the advanced allograft therapies we provide for surgeons.”
Muhle told OTW, “Having held roles with financial and operational responsibilities for companies ranging in size, I am looking forward to the opportunity to lead AlloSource’s finance, accounting, and information technology teams. I’ve worked in a variety of industries and understand the complexities of this role. Working for a mission-driven organization that impacts patients’ lives each day is a great blend of my professional and personal passions.”
“The hardworking teams at AlloSource are motivated by the organization’s role in helping patients heal, and one of my main focuses will be driving efforts that support the needs of our surgeon customers. Looking ahead to the next year and beyond, we will continue to find new ways to provide the advanced solutions that help recipients return to an active lifestyle.”
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.